PSMA PET and Salvage Radiation After Prostatectomy

Short answer: PSMA PET can reveal recurrent prostate cancer that conventional scans may miss and can change a salvage radiation plan. However, the scan is not perfectly sensitive—especially when PSA is low. Current guidance says a negative PSMA PET should not, by itself, be a reason to withhold prostate-bed salvage radiation.

What is biochemical recurrence?

After prostatectomy, PSA is expected to fall to a very low or undetectable level. A persistently detectable or rising PSA may be the first sign that prostate cancer remains, even when there are no symptoms and conventional CT or bone scans are normal.

This is called biochemical recurrence. Salvage radiation aims to treat likely microscopic disease while it may still be confined to the prostate bed or nearby lymphatic regions.

What makes PSMA PET different?

Prostate-specific membrane antigen, or PSMA, is a protein expressed at high levels by many prostate cancer cells. A PSMA-targeted radioactive tracer can make sites of disease visible on PET imaging.

Compared with conventional imaging, PSMA PET is generally better at finding small-volume recurrence. It may show:

• recurrence in the prostate bed;
• pelvic or more distant lymph nodes;
• bone metastases; or
• disease outside a planned radiation field.

The information may change the radiation target, prompt metastasis-directed treatment, or lead to discussion of systemic therapy.

What does the 2024 guideline recommend?

The AUA/ASTRO/SUO salvage therapy guideline states that clinicians may obtain PSMA PET instead of conventional imaging—or after negative conventional imaging—for biochemical recurrence. It also recommends next-generation molecular PET imaging when salvage radiation is being considered after prostatectomy.

These recommendations are conditional because high-quality evidence showing that PSMA PET improves long-term survival is still developing. Better detection does not automatically prove better outcomes.

Why can a negative PSMA PET be misleading?

At a low PSA, recurrent deposits may be too small for any scan to detect. The guideline summarizes PSMA PET detection rates of roughly:

• 31% to 42% when PSA is below 0.5 ng/mL;
• 45% to 57% from 0.5 to below 1.0 ng/mL; and
• progressively higher rates as PSA rises.

The exact rate varies by tracer, study, and patient population. A negative result therefore means “not seen,” not necessarily “not present.”

Imaging should not create a treatment delay

Salvage radiation tends to be more effective when delivered at a lower PSA. The guideline advises clinicians not to withhold prostate-bed salvage radiation solely because molecular PET is negative.

This creates an important balance:

• waiting may make disease easier to see;
• but waiting may also allow more cancer cells to spread and reduce the chance that local salvage treatment succeeds.

A radiation oncologist can use PSA trend, pathology, risk features, prior imaging, and health history to interpret a scan in context.

What remains under study?

The PSMA-SRT phase 3 trial is testing whether adding PSMA PET to salvage radiation planning improves progression outcomes. The trial is active but no longer recruiting, with later completion expected. Until mature outcome results are available, claims should focus on PSMA PET's established diagnostic and planning value rather than promising that scan-guided changes improve survival.

Questions to ask after a rising PSA

1. How quickly is my PSA rising?
2. At what PSA should salvage radiation begin?
3. Is PSMA PET likely to find disease at my current PSA?
4. Would a positive result change the treatment field?
5. If the scan is negative, what evidence supports treating the prostate bed?
6. Should pelvic lymph nodes or hormone therapy be included?

PSMA PET is a powerful planning tool, but it is one part of a time-sensitive salvage decision—not a pass-or-fail test for whether cancer exists.

Questions patients often ask

What PSA level is needed for PSMA PET?

There is no single cutoff, but detection rates rise as PSA rises. A scan can be useful at a low PSA, yet it may miss microscopic disease. Imaging timing should be coordinated with the salvage treatment decision.

Should salvage radiation wait until PSMA PET is positive?

Not necessarily. The 2024 guideline says clinicians should not withhold prostate-bed salvage radiation solely because a molecular PET scan is negative.

Can PSMA PET change the radiation field?

Yes. A positive scan may identify lymph nodes, bone lesions, or disease elsewhere that changes the target or prompts discussion of systemic therapy. Whether that change improves long-term outcomes is still being studied.

Sources and further reading

1. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I. The Journal of Urology (2024).
2. AUA/ASTRO/SUO Guideline on Salvage Therapy for Prostate Cancer. American Society for Radiation Oncology (2024).
3. Phase III Randomized Trial of PSMA PET for Salvage Radiotherapy Planning. ClinicalTrials.gov (2026).